Table of Contents
- Trial overview
- Who the studies are for
- What the trials are measuring
- Trial phases and study size
- How the studies are designed
- Key points for patients
Trial overview
Two authorised interventional trials are studying Siponimod in people with progressive multiple sclerosis.[1][2] One trial focuses on the effect of treatment on paramagnetic rim lesions, which are MRI findings linked with ongoing inflammation.[1] The other trial looks at chronic inflammation inside the nervous system by measuring markers in blood and cerebrospinal fluid.[2]
Who the studies are for
One study includes people with an active progressive multiple sclerosis course after an initial relapse clinical course.[1] This means the disease started with relapses, then became steadily progressive while still showing activity.[1] The other study includes patients with secondary progressive MS.[2]
In simple terms, these trials are not for all forms of multiple sclerosis; they focus on people whose disease has already moved into a progressive stage.[1][2]
What the trials are measuring
The first trial uses MRI-based change in the susceptibility of rim lesions as its main endpoint.[1] The researchers compare the change after Siponimod with the natural change seen before treatment in the same person, so each patient serves as their own comparison.[1]
The second trial measures changes in cerebrospinal fluid markers of chronic intrathecal inflammation, with a special focus on CXCL13.[2] The study description says CXCL13 is linked with B-cell accumulation and with disease severity and progression.[2] This trial also follows paired blood and cerebrospinal fluid samples over at least two years.[2]
Trial phases and study size
Both Siponimod studies are Phase 3 trials.[1][2] Phase 3 studies are later-stage clinical trials that look at how well a treatment works in a defined patient group and continue to collect important study data.[1][2]
The planned enrollment is 60 people in the MRI-focused study and 40 people in the inflammation-focused study.[1][2] These are relatively small, focused studies rather than very large population trials.[1][2]
How the studies are designed
Both trials are interventional, which means the researchers give a treatment and then measure what happens.[1][2] The study records list Siponimod under the product name Mayzent and also under the development code BAF312 in the first trial.[1] In the second trial, the treatment is listed as Mayzent 0.25 mg and 2 mg film-coated tablets.[2]
The first study uses an internal comparison, meaning it compares each person’s results after treatment with their own recent pre-treatment period.[1] The second study follows people for at least two years and looks at paired blood and spinal fluid samples over time.[2]
Key points for patients
These trials are trying to learn whether Siponimod changes signs of disease activity in progressive multiple sclerosis.[1][2] One trial looks mainly at MRI lesions, while the other looks mainly at immune markers in spinal fluid.[1][2]
The target groups are people with active progressive MS and people with secondary progressive MS.[1][2] Both studies are in Phase 3 and are designed to give more detailed evidence about treatment effects in these specific patient groups.[1][2]
